Results 11 to 20 of about 3,401,781 (173)

A Case of Cytokine Release Syndrome (CRS) Related to Treatment With Lenvatinib Plus Pembrolizumab for Metastatic Clear Cell Renal Cell Carcinoma [PDF]

open access: yesIJU Case Reports
Introduction Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infection and immunotherapy. Due to its nonspecific presentation, distinguishing CRS from other life‐threatening conditions remains ...
Kei Nagase   +9 more
doaj   +6 more sources

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023. [PDF]

open access: yesHum Vaccin Immunother, 2023
CAR-T cell therapy has demonstrated efficacy in treating certain hematological malignancies. However, the administration of CAR-T cells is accompanied by the occurrence of adverse events.
Li H, Huang Q, Zhang Y.
europepmc   +5 more sources

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies. [PDF]

open access: yesClin Cancer Res, 2023
Abstract Purpose: Target-dependent TCB activity can result in the strong and systemic release of cytokines that may develop into cytokine release syndrome (CRS), highlighting the need to understand and prevent this complex clinical syndrome.
Leclercq-Cohen G   +22 more
europepmc   +3 more sources

Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures [PDF]

open access: yesFrontiers in Immunology, 2023
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and ...
Deep Shah, Brian Soper, Lindsay Shopland
doaj   +2 more sources

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? [PDF]

open access: yesFront Med (Lausanne), 2020
The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health
Liu D, Zhang T, Wang Y, Xia L.
europepmc   +5 more sources

Cytokine release syndrome [PDF]

open access: yesJournal for ImmunoTherapy of Cancer, 2018
During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody ...
Alexander Shimabukuro-Vornhagen   +8 more
doaj   +3 more sources

Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations

open access: yesCurrent Oncology
Background: Cytokine Release Syndrome (CRS) is a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs).
Panos Arvanitis   +3 more
doaj   +2 more sources

Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of the Cytokine Release Syndrome

open access: yesCells, 2023
We discovered a novel therapeutic target critical for SARS-CoV-2, cellular infectivity and the induction of the cytokine release syndrome. Here, we show that the mammalian enzyme neuraminidase-1 (Neu-1) is part of a highly conserved signaling platform ...
William W. Harless   +4 more
doaj   +2 more sources

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome [PDF]

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2020
Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening.
Tom van Kraaij   +7 more
doaj   +2 more sources

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. [PDF]

open access: yesBlood Cancer J, 2023
Scott SA   +9 more
europepmc   +4 more sources

Home - About - Disclaimer - Privacy